source
- Merck and Moderna release early phase 3 melanoma vaccine data showing primary endpoint success but weaker secondary resultsMerck and Moderna disclosed phase 3 data for their melanoma vaccine INTerpath-001 ahead of schedule after an embargo breach. The trial met its primary endpoint of recurrence‑free survival, with re…
- FDA approves GSK‑Ionis hepatitis B functional cure, Hibsago, targeting undetectable virus after six monthsThe FDA has approved bepirovirsen, an antisense oligonucleotide from GSK and Ionis, for chronic hepatitis B infection. It will be sold under the brand name Hibsago. The therapy is described as a f…